Acrux Limited announced over 50% enrolment completion in its international phase III clinical trial of Testosterone MD-Lotion(R).  A report on the results is expected by the end of 2009.

SurModics, Inc., announced in company structural changes designed to cut costs while maximizing customer service and effective operations.

Delcath Systems, Inc. announced that it has been granted orphan-drug applications by the United States Food and Drug Administration (FDA) for its drug melphalan to treat both cutaneous and ocular melanomas.

IDM Pharma, Inc. has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) and the recommendation to grant centralized marketing authorization for mifamurtide (L-MTP-PE), known as MEPACT(R) in Europe, for the treatment of patients with non-metastatic, resectable osteosarcoma. Final approval from the European Commission is expected in early 2009 once the recommendation has been adopted at the next CHMP meeting.